DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Stebbing J, Baranau YV, Baryash V. et al.
Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer. ASCO 2017, Poster 510.
We do not assume any responsibility for the contents of the web pages of other providers.